As activated myr-p110α by itself had minimal transforming activity (Supplementary Figure 2) and the p53 gene is the second most frequently mutated gene in breast cancer,8, 24 we assessed the effect of myr-p110α and homozygous p53 deletion on breast tumor development. This evidence concerns the gene TP53 and breast carcinoma.